We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of transrectal ultrasound-based dosimetry for brachytherapy of prostate cancer: a single-center experience.
- Authors
Changzhao Yang; Zhengtong Lv; Lingxiao Chen; Jie Wang; Xiheng Hu; Chand, Harripersaud; Xi Sun; Guyu Tang; Congyi Tang; Huichuan Jiang; Yuan Li
- Abstract
Purpose: To explore the possibility of intraoperative transrectal ultrasound (TRUS)-based dose verification in trans- perineal brachytherapy (BT) with iodine-125 (125I) seeds for prostate cancer. Material and methods: Fifteen patients with prostate cancer were treated using BT with 125I seeds. Post-implant TRUS and computed tomography (CT) images were imported into treatment planning system (TPS) for dosimetry. Dosimetry parameters, including minimum dose received by 90% of the volume (D90), percentage of the volume receiving 100% of prescribed dose (V100), and percentage of the volume receiving 200% of prescribed dose (V200) were calculated based on TRUS and CT images, separately. The D90 value of TRUS-based dosimetry was transformed to its expected value. Comparisons of the dosimetric parameters between post-operative verification and preoperative plans were made by paired t-test. One-way ANOVA model was used to assess the differences in preoperative plans. Agreements were evaluated between the preoperative planning and post-operative actual dose parameters using Bland-Altman analysis. Results: In total, 825 of 125I seeds were implanted successfully in 15 patients. In TRUS-based dosimetry, 674 seeds (81%) were identified clearly in TRUS-based images, and the expected value of D90 parameter showed no significant differences compared with the preoperative planning and CT post-operation results (p > 0.05). In CT-based dosimetry, 810 seeds (98%) were identified clearly in CT-based images, and there was good consistency of D90, V100, and V200 values (p > 0.05). Post-implant CT-based dosimetry indicated that 125I seed implantation had fulfilled the expected plan. Conclusions: Intraoperative TRUS can be used for dosimetric verification of BT for prostate cancer.
- Subjects
HIGH dose rate brachytherapy; ENDORECTAL ultrasonography; RADIATION dosimetry; PROSTATE cancer; RADIOISOTOPE brachytherapy; PROSTATE cancer patients; EXPECTED returns
- Publication
Journal of Contemporary Brachytherapy, 2020, Vol 12, Issue 4, p327
- ISSN
1689-832X
- Publication type
Article
- DOI
10.5114/jcb.2020.98111